Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,18258501,flow rate,"Ecabet and the I.S. valsartan were separated on a Venusil MP C18 analytical column using methanol-10mM ammonium acetate (75:25, v/v, pH 3.0) as mobile phase at a flow rate of 1.0 mL/min.",Determination of ecabet in human plasma by high-performance liquid chromatography-tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18258501/),[ml] / [min],1.0,108225,DB05265,Ecabet
,1779408,absorption,The absorption was estimated to be 3.4-7.0% of dose in rats.,"Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1- methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogs. ",ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1779408/),%,3.4-7.0,179626,DB05265,Ecabet
,1779408,elimination half lives (beta),"The plasma radioactivity after oral dosing peaked at 5-6 h in rats and at 2 h in dogs, and their elimination half lives (beta) were about 120-130 h.","Metabolic fate of a new anti-ulcer drug (+)-(1R,4aS,10aR)- 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1- methylethyl)-6-sulfo-1-phenanthrenecarboxylic acid 6-sodium salt pentahydrate (TA-2711). I. Disposition, metabolism and protein binding in rats and dogs. ","t1/2,Î²-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1779408/),h,120-130,179627,DB05265,Ecabet
